Pioneer Group, a specialist in life science infrastructure and venture building, has teamed up with global healthcare company Novo Nordisk to launch a Golden Ticket designed to help accelerate innovations in cardiometabolic diseases, rare blood and rare endocrine disorders. The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic disease, with robust research plans and potential for successful research development. Pioneer Group and Novo Nordisk want to hear from science and technology founders as…

AMSBIO offers a production service for high quality custom transduction-ready viral particles designed to support your research and save you valuable time. Drawing upon extensive knowledge in research areas including Adeno Associated Virus, Adenovirus, Herpes Simplex Virus, Lentivirus, MMLV Retrovirus and more - AMSBIO viral services include the design and construction of the vectors, ultimately providing you with high quality viral particles that you can rely on. Maja Petkovic, AMSBIO business unit manager commented “Recently we supplied a custom lentiviral vector to…

MetX funded by $1M grant from Metrodora Foundation to accelerate research for complex multisystem disordersSALT LAKE CITY, UT and OXFORD, UK – 18 September 2024 – PrecisionLife, a leading clinical-stage precision medicine company focused on chronic diseases, and Metrodora Institute, an advanced US research and healthcare center, have begun sharing the first research results with participants from Metrodora’s MetX study. The Metrodora Foundation, a leading 501(c)(3) nonprofit, provided critical funding to launch MetX with a generous $1M grant. This marks a significant breakthrough in…

Sanger sequencing is utilised to understand the arrangement of nucleotides within a sequence of DNA. This technique offers 99.99% reliability, enhanced sensitivity due to its sequencing depth, and the ability to provide sequencing information from even the most deteriorated DNA samples. Read our latest blog here: https://sourcebioscience.com/how-can-you-benefit-from-outsourcing-seque…

Applications open for Discovery Park’s ‘Discovery Spark’ programme  Prize package worth over £50,000, including free lab or office space for one year at Discovery Park and a package of support from a number of specialist partners. Deadline for initial applications closes midnight on 24th September 2024    Sandwich, Kent, UK / 12 September 2024 / Leading science and innovation campus, Discovery Park, in Sandwich, Kent has launched applications for the third cohort of its immersive business growth competition, ‘Discovery Spark’.    The programme equips early…

Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule Stevenage, UK, 5 September 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces its conference attendance programme for the remainder of 2024. Forthcoming events include: • ISCT Europe Regional Meeting, 4 – 6 September in Gothenburg - speaking • Healthtech Innovation Day, 17 – 18 September in Paris - speaking, investor meetings • Sachs Biotech in Europe Forum,…

NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND Stevenage, UK, 5 August 2024 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation. It is one of five recipients of the 2024 In Vivo Target Validation grants in collaboration with Biospective. The funding will be used to support its discovery programme for a treatment for Amyotrophic Lateral Sclerosis (ALS) (also known as…

Read eNews for September here Featuring: ✅ Tony Jones, CEO, One Nucleus monthly news ✅ Are You Targeting Your Advertising Spend for the Best Return? by Alicia Gailliez ✅ Has Biotech Investment Turned a Corner? - BioIndustry Association (BIA) ✅ What’s Hot in the Diagnostic Deal Space? - PharmaVentures  ✅ What were the top 10 locations for UK Life Science investment in the UK in 1H 2024? - Pioneer Group ✅ The Role of Innovative R&D and GenAI in Helping to Tackle AMR - Deloitte ✅ Don't Miss Your Opportunities at BIO-Europe - Deadlines Approaching! -EBD Group Sponsored by…

Merck’s EMEA Advance Biotech Grant Program Merck’s EMEA Advance Biotech Grant Program https://informaconnect.com/bioeurope/merck-advance-biotech-grant/ is designed to support emerging biotech companies on the forefront of innovative drug development. Targeted at biotechs with a focus on novel modalities and therapeutics, this program aids companies with at least one biologic in the pipeline, particularly those working on mAbs, ADCs, mRNA, gene therapy, cell therapy, and vaccines. The program offers significant prizes: the winner receives €148,400 in bioprocessing technologies, consultation…

Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies Company Secures Additional Financing to Advance Clinical Programmes in Immuno-Oncology and Inflammatory Bowel Disease Through to Data Readout Cambridge, UK – 27 August 2024: Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), is pleased to announce that it has received regulatory approvals to initiate clinical studies for its first two programmes in advanced melanoma (MELODY-1…